Polygenic hazard score is associated with prostate cancer in multi-ethnic populations
-
Published:2021-02-23
Issue:1
Volume:12
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Huynh-Le Minh-PhuongORCID, , Fan Chun ChiehORCID, Karunamuni Roshan, Thompson Wesley K., Martinez Maria Elena, Eeles Rosalind A.ORCID, Kote-Jarai Zsofia, Muir KennethORCID, Schleutker JohannaORCID, Pashayan NoraORCID, Batra JyotsnaORCID, Grönberg HenrikORCID, Neal David E., Donovan Jenny L., Hamdy Freddie C., Martin Richard M.ORCID, Nielsen Sune F., Nordestgaard Børge G.ORCID, Wiklund FredrikORCID, Tangen Catherine M., Giles Graham G.ORCID, Wolk AlicjaORCID, Albanes Demetrius, Travis Ruth C.ORCID, Blot William J., Zheng WeiORCID, Sanderson Maureen, Stanford Janet L., Mucci Lorelei A., West Catharine M. L.ORCID, Kibel Adam S., Cussenot Olivier, Berndt Sonja I., Koutros Stella, Sørensen Karina DalsgaardORCID, Cybulski Cezary, Grindedal Eli Marie, Menegaux Florence, Khaw Kay-Tee, Park Jong Y.ORCID, Ingles Sue A., Maier Christiane, Hamilton Robert J., Thibodeau Stephen N., Rosenstein Barry S., Lu Yong-Jie, Watya Stephen, Vega AnaORCID, Kogevinas Manolis, Penney Kathryn L., Huff Chad, Teixeira Manuel R.ORCID, Multigner LucORCID, Leach Robin J., Cannon-Albright LisaORCID, Brenner Hermann, John Esther M., Kaneva Radka, Logothetis Christopher J., Neuhausen Susan L., De Ruyck Kim, Pandha Hardev, Razack Azad, Newcomb Lisa F., Fowke Jay H., Gamulin MarijaORCID, Usmani Nawaid, Claessens Frank, Gago-Dominguez Manuela, Townsend Paul A., Bush William S.ORCID, Roobol Monique J.ORCID, Parent Marie-Élise, Hu Jennifer J., Mills Ian G., Andreassen Ole A.ORCID, Dale Anders M., Seibert Tyler M.ORCID, , , , , ,
Abstract
AbstractGenetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p < 10−180). Comparing the 80th/20th PHS2 percentiles, hazard ratios for prostate cancer, aggressive cancer, and prostate-cancer-specific death are 5.32, 5.88, and 5.68, respectively. Within European, Asian, and African ancestries, hazard ratios for prostate cancer are: 5.54, 4.49, and 2.54, respectively. PHS2 risk-stratifies men for any, aggressive, and fatal prostate cancer in a multi-ethnic dataset.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference56 articles.
1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015). 2. Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016). 3. Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. N. Engl. J. Med. 379, 2319–2329 (2018). 4. Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009). 5. Jones, C. U. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365, 107–118 (2011).
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|